• 1
    Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):12061252.
  • 2
    Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the Internation Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525541.
  • 3
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:20492051.
  • 4
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 5
    Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:17551762.
  • 6
    Obisean TO, Vargas CM, Gillum RF. Geographic variation in stroke risk in the United States. Region, urbanization, and hypertension in the Third National Health and Nutrition Examination Survey. Stroke. 2000;31:1925.
  • 7
    Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men: 16-year MR-FIT findings. JAMA. 1997;277:12931298.
  • 8
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290(2):199206.
  • 9
    Rothwell PM. External validity of randomized controlled trials: to whom do the results of this trial apply? Lancet. 2005;365:8293.
  • 10
    White WB, Giles T, Bakris GL, et al. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure in the primary care setting. Am Heart J. 2005. In press.
  • 11
    McGill JB, Rilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled parallel-group trial. Clin Ther. 2001;23:833850.
  • 12
    Giles TD, Bakris GL, Smith DH, et al. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens. 2003;16:460466.
  • 13
    Perloff D, Grim C, Flack J, et al. Human blood pressure determination by sphygmomanometry. Circulation. 1993;88:24602467.
  • 14
    O'Brien E, Mee F, Atkins N, et al. Accuracy of the Spacelabs 90207 determined by the British Hypertension Society Protocol. J Hypertens. 1991;9(suppl 5):S25S31.
  • 15
    White WB. Ambulatory blood pressure monitoring in clinical practice. N Engl J Med. 2003;348:23772378.
  • 16
    Neutel JM, Smith DHG, Weber MA, et al. Use of olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich). 2004;6:168174.
  • 17
    White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan vs valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens. 2004;17:347353.
  • 18
    Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker losartan. Arch Intern Med. 1995;155:405411.
  • 19
    Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci. 2002;324:127137.
  • 20
    Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914921.